A novel anti-CEACAM5 monoclonal antibody, CC4, suppresses colorectal tumor growth and enhances NK cells-mediated tumor immunity.

Carcinoembryonic antigen (CEA, CEACAM5, and CD66e) has been found to be associated with various types of cancers, particularly colorectal carcinoma, and developed to be a molecular target for cancer diagnosis and therapy. In present study, we generated a novel anti-CEACAM5 monoclonal antibody, namel...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Chaogu Zheng, Jing Feng, Di Lu, Ping Wang, Shu Xing, Jean-Luc Coll, Dongling Yang, Xiyun Yan
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2011
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/f470a044dc7b4305b9f30b2c55428f36
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:f470a044dc7b4305b9f30b2c55428f36
record_format	dspace
spelling	oai:doaj.org-article:f470a044dc7b4305b9f30b2c55428f362021-11-18T06:51:34ZA novel anti-CEACAM5 monoclonal antibody, CC4, suppresses colorectal tumor growth and enhances NK cells-mediated tumor immunity.1932-620310.1371/journal.pone.0021146https://doaj.org/article/f470a044dc7b4305b9f30b2c55428f362011-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/21731662/pdf/?tool=EBIhttps://doaj.org/toc/1932-6203Carcinoembryonic antigen (CEA, CEACAM5, and CD66e) has been found to be associated with various types of cancers, particularly colorectal carcinoma, and developed to be a molecular target for cancer diagnosis and therapy. In present study, we generated a novel anti-CEACAM5 monoclonal antibody, namely mAb CC4, by immunizing mice with living colorectal cancer LS174T cells. Immunohistochemical studies found that mAb CC4 specifically and strongly binds to tumor tissues, especially colorectal adenocarcinoma. In xenografted mice, mAb CC4 is specifically accumulated in tumor site and remarkably represses colorectal tumor growth. In vitro functional analysis showed that mAb CC4 significantly suppresses cell proliferation, migration and aggregation of colorectal cancer cells and also raises strong ADCC reaction. More interestingly, mAb CC4 is able to enhance NK cytotoxicity against MHC-I-deficient colorectal cancer cells by blocking intercellular interaction between epithelial CEACAM5 and NK inhibitory receptor CEACAM1. These data suggest that mAb CC4 has the potential to be developed as a novel tumor-targeting carrier and cancer therapeutic.Chaogu ZhengJing FengDi LuPing WangShu XingJean-Luc CollDongling YangXiyun YanPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 6, Iss 6, p e21146 (2011)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Chaogu Zheng Jing Feng Di Lu Ping Wang Shu Xing Jean-Luc Coll Dongling Yang Xiyun Yan A novel anti-CEACAM5 monoclonal antibody, CC4, suppresses colorectal tumor growth and enhances NK cells-mediated tumor immunity.
description	Carcinoembryonic antigen (CEA, CEACAM5, and CD66e) has been found to be associated with various types of cancers, particularly colorectal carcinoma, and developed to be a molecular target for cancer diagnosis and therapy. In present study, we generated a novel anti-CEACAM5 monoclonal antibody, namely mAb CC4, by immunizing mice with living colorectal cancer LS174T cells. Immunohistochemical studies found that mAb CC4 specifically and strongly binds to tumor tissues, especially colorectal adenocarcinoma. In xenografted mice, mAb CC4 is specifically accumulated in tumor site and remarkably represses colorectal tumor growth. In vitro functional analysis showed that mAb CC4 significantly suppresses cell proliferation, migration and aggregation of colorectal cancer cells and also raises strong ADCC reaction. More interestingly, mAb CC4 is able to enhance NK cytotoxicity against MHC-I-deficient colorectal cancer cells by blocking intercellular interaction between epithelial CEACAM5 and NK inhibitory receptor CEACAM1. These data suggest that mAb CC4 has the potential to be developed as a novel tumor-targeting carrier and cancer therapeutic.
format	article
author	Chaogu Zheng Jing Feng Di Lu Ping Wang Shu Xing Jean-Luc Coll Dongling Yang Xiyun Yan
author_facet	Chaogu Zheng Jing Feng Di Lu Ping Wang Shu Xing Jean-Luc Coll Dongling Yang Xiyun Yan
author_sort	Chaogu Zheng
title	A novel anti-CEACAM5 monoclonal antibody, CC4, suppresses colorectal tumor growth and enhances NK cells-mediated tumor immunity.
title_short	A novel anti-CEACAM5 monoclonal antibody, CC4, suppresses colorectal tumor growth and enhances NK cells-mediated tumor immunity.
title_full	A novel anti-CEACAM5 monoclonal antibody, CC4, suppresses colorectal tumor growth and enhances NK cells-mediated tumor immunity.
title_fullStr	A novel anti-CEACAM5 monoclonal antibody, CC4, suppresses colorectal tumor growth and enhances NK cells-mediated tumor immunity.
title_full_unstemmed	A novel anti-CEACAM5 monoclonal antibody, CC4, suppresses colorectal tumor growth and enhances NK cells-mediated tumor immunity.
title_sort	novel anti-ceacam5 monoclonal antibody, cc4, suppresses colorectal tumor growth and enhances nk cells-mediated tumor immunity.
publisher	Public Library of Science (PLoS)
publishDate	2011
url	https://doaj.org/article/f470a044dc7b4305b9f30b2c55428f36
work_keys_str_mv	AT chaoguzheng anovelanticeacam5monoclonalantibodycc4suppressescolorectaltumorgrowthandenhancesnkcellsmediatedtumorimmunity AT jingfeng anovelanticeacam5monoclonalantibodycc4suppressescolorectaltumorgrowthandenhancesnkcellsmediatedtumorimmunity AT dilu anovelanticeacam5monoclonalantibodycc4suppressescolorectaltumorgrowthandenhancesnkcellsmediatedtumorimmunity AT pingwang anovelanticeacam5monoclonalantibodycc4suppressescolorectaltumorgrowthandenhancesnkcellsmediatedtumorimmunity AT shuxing anovelanticeacam5monoclonalantibodycc4suppressescolorectaltumorgrowthandenhancesnkcellsmediatedtumorimmunity AT jeanluccoll anovelanticeacam5monoclonalantibodycc4suppressescolorectaltumorgrowthandenhancesnkcellsmediatedtumorimmunity AT donglingyang anovelanticeacam5monoclonalantibodycc4suppressescolorectaltumorgrowthandenhancesnkcellsmediatedtumorimmunity AT xiyunyan anovelanticeacam5monoclonalantibodycc4suppressescolorectaltumorgrowthandenhancesnkcellsmediatedtumorimmunity AT chaoguzheng novelanticeacam5monoclonalantibodycc4suppressescolorectaltumorgrowthandenhancesnkcellsmediatedtumorimmunity AT jingfeng novelanticeacam5monoclonalantibodycc4suppressescolorectaltumorgrowthandenhancesnkcellsmediatedtumorimmunity AT dilu novelanticeacam5monoclonalantibodycc4suppressescolorectaltumorgrowthandenhancesnkcellsmediatedtumorimmunity AT pingwang novelanticeacam5monoclonalantibodycc4suppressescolorectaltumorgrowthandenhancesnkcellsmediatedtumorimmunity AT shuxing novelanticeacam5monoclonalantibodycc4suppressescolorectaltumorgrowthandenhancesnkcellsmediatedtumorimmunity AT jeanluccoll novelanticeacam5monoclonalantibodycc4suppressescolorectaltumorgrowthandenhancesnkcellsmediatedtumorimmunity AT donglingyang novelanticeacam5monoclonalantibodycc4suppressescolorectaltumorgrowthandenhancesnkcellsmediatedtumorimmunity AT xiyunyan novelanticeacam5monoclonalantibodycc4suppressescolorectaltumorgrowthandenhancesnkcellsmediatedtumorimmunity
_version_	1718424329114353664

A novel anti-CEACAM5 monoclonal antibody, CC4, suppresses colorectal tumor growth and enhances NK cells-mediated tumor immunity.

Ejemplares similares